Canadian Journal of Gastroenterology and Hepatology / 2021 / Article / Tab 3 / Research Article
Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study Table 3 Clinical features and laboratory results of patients with primary biliary cholangitis and those with primary biliary cholangitis complicated with autoimmune hepatitis.
Parameters PBC group (n = 328) PBC-AIH group (n = 36) ALT (U/L) 56.60 (28.70–111.10) 71.2 (30.75–155.38) 0.208 AST (U/L) 70.30 (41.55–114.90) 90.55 (49.18–210.83) 0.079 TBIL (μ mol/L) 27.80 (14.90–75.30) 30.35 (17.73–155.56) 0.393 DBIL (μ mol/L) 15.00 (5.80–53.35) 16.10 (7.43–89.83) 0.368 TP (g/L) 70.60 (63.60–76.70) 72.05 (67.36–78.78) 0.174 ALB (g/L) 34.80 (29.60–38.80) 33.30 (27.35–37.48) 0.094 GGT (U/L) 168.5 (76.9–358.8) 121.70 (75.40–318.25) 0.416 ALP (U/L) 189.30 (114.40–340.80) 169.05 (101.33–289.08) 0.312 WBC count (109/L) 4.63 (3.42–6.30) 3.22 (2.58–4.22) 0.892 NE% (%) 59.06 (50.38–68.90) 58.8 (49.85–65.74) 0.338 Hb (g/L) 114.6 (98.60–128.00) 112.9 (79.8–121.8) 0.516 PLT (109/L) 129.90 (77.30–196.20) 122.30 (85.38–165.95) 0.886 PT (s) 12.30 (11.10–14.10) 12.80 (11.60–17.30) 0.021 APTT (s) 34.30 (30.83–37.75) 35.70 (30.15–40.75) 0.398 UREA (mmol/L) 4.85 (3.82–6.58) 5.05 (3.76–6.11) 0.813 CREA (mmol/L) 57.00 (50.00–67.95) 58.80 (47.25–68.50) 0.833 IgM (g/L) 2.79 (1.58–4.25) 2.68 (1.43–4.35) 0.963 IgG (g/L) 15.40 (12.50–19.00) 16.45 (13.83–25.33) 0.046 AFP (ng/mL) 3.70 (2.58–5.50) 4.25 (3.13–6.18) 0.052 TC (mmol/L) 4.29 (3.39–5.49) 4.44 (2.91–5.62) 0.65 TG (mmol/L) 1.05 (0.66–1.58) 1.14 (0.81–1.64) 0.264 HDL-C (mmol/L) 1.08 (0.60–1.51) 0.92 (0.40–1.28) 0.052 LDL-C (mmol/L) 2.32 (1.69–3.04) 2.36 (1.45–3.52) 0.822 Ca2+ (mmol/L) 2.18 (2.06–2.27) 2.15 (2.02–2.27) 0.327 PHOS (mmol/L) 1.08 (0.96–1.20) 1.05 (0.90–1.21) 0.268 ANA+ 164/280 (58.6%) 26/33 (78.8%) 0.025 ACA+ 60/319 (18.81%) 5/35 (14.29%) 0.512 SS-A/Ro-52kD+ 95/287 (33.10%) 13/34 (38.24%) 0.549 AMA+ 218/312 (69.9%) 22/35 (62.9%) 0.394 AMA-M2+ 191/314 (60.80%) 19/35 (54.3%) 0.453 Fatigue 132/328 (40.24%) 15/36 (41.67%) 0.869 Pruritus 44/328 (40.24%) 3/36 (8.33%) 0.388 Cirrhosis 219/328 (66.77%) 29/36 (80.56%) 0.092 Child–Pugh score 6.00 (5.00–8.00) 6.50 (5.00–9.00) 0.111 Child–Pugh score ≥7 141/328 (42.99%) 18/36 (50.00%) 0.421 Fibrosis-4 4.79 (2.37–8.93) 5.54 (3.02–9.50) 0.187 GLOBE score 1.83 ± 1.49 1.95 ± 1.47 0.400
PBC: primary biliary cholangitis; PBC-SS: primary biliary cholangitis complicated with Sjögren’s syndrome; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBIL: total bilirubin; DBIL: direct bilirubin; TP: serum total protein; ALB: albumin; GGT: Gamma-glutamyl transferase; ALP: alkaline phosphatase; WBC count: white blood cell count; NE%: neutrophil percentage; Hb: hemoglobin; PLT: platelet count; PT: prothrombin time; APTT: activated partial thromboplastin time; CREA: creatinine; IgM: immunoglobulin M; IgG: immunoglobulin G; AFP: alpha-1-fetoprotein; TC: total cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Ca
2+ : serum calcium; PHOS: serum phosphorus; ANA+: antinuclear antibody-positive; ACA+: anticentromere antibody-positive; SS-A/Ro-52kD: anti-SSA/Ro-52kD antibody-positive; AMA: antimitochondrial antibody-positive; AMA-M2+: antimitochondrial antibody-M2 mitochondrial subfraction-positive;
value < 0.05 was considered significant.
